消化系統領域的合作與授權協議（2016-2026）

消化系統領域併購的決定性指標

消化系統領域的合作涵蓋了廣泛的適應症、治療方法和研發階段，其交易結構反映了該領域疾病領域和治療方法的多樣性。

本報告對消化系統領域的 432 項合作與許可協議進行了全面系統的分析，清楚地展示了整個市場合作的設計、談判和執行方式，並以證據為基礎進行了闡述。

清楚了解市場標準

本報告將幫助您準確了解消化系統交易的實際結構，並使您能夠：

• 自信地對標類似交易
• 對相關交易中的預付款、里程碑付款和特許權使用費結構進行詳細分析。
• 設定切合實際的市場參數
• 您可以深入了解交易條款如何因階段、資產類型和合作夥伴情況而異。
• 支持實證評估和結構性決策
• 我們將根據實際交易數據進行內部討論，而不是根據假設。
• 了解主要企業如何進行交易。
• 在日益多元化和不斷發展的治療領域中，可視化合作夥伴的行為和重複交易結構。
• 全面了解交易結構和執行情況
• 本報告超越了表面的交易數據，提供了對底層合約文件的訪問，使您能夠詳細了解實際合約是如何構建的。

這包括：

• 授予和保留的權利
• 負責開發和商業化
• 財務結構和支付觸發機制
• 關鍵合約條款和保障措施
• 這種程度的透明度對於了解消化系統合作中價值、風險和控制是如何分配的至關重要，尤其是在慢性疾病和多樣化的疾病環境中。
• 專為實際業務發展和策略制定而設計。

本報告廣泛用於以下用途：

• 建置和基準測試實際交易
• 在清晰的市場環境下準備談判
• 合作機會及目的地評估
• 支援穩健且引人注目的數據驅動型內部策略
• 內容
• 432項消化系統領域的合作與授權協議
• 財務條款，包括預付款、里程碑付款和版稅（如有揭露）。
• 可全文搜尋的合約目錄（依公司、治療領域及技術分類）
• 可直接查閱向美國證券交易委員會提交的合約和原始文件。
• 分析交易趨勢、重大交易和活躍的交易商。
• 關於胃腸道領域交易的可靠、基於證據的參考資料。
• 本報告結合全面的交易報告和合約層面的深入分析，為如何在胃腸病學領域建立、談判和評估合作夥伴關係提供了可靠的、基於證據的參考資料。

目錄

摘要整理

第1章：引言

第2章：消化系統交易趨勢

• 介紹
• 在消化系統領域長期合作
• 消化系統領域的合夥企業（按交易類型分類）
• 消化系統領域的合作（按產業分類）
• 消化系統領域的合作（依發展階段分類）
• 消化系統領域的合作（按技術類型分類）
• 在消化系統領域進行合作（依治療適應症分類）

第3章消化系統協作中的財務交易條款

• 介紹
• 消化系統合作的財務條款將予以披露。
• 消化系統協作的關鍵價值觀
• 預付胃腸道治療費用
• 消化系統相關合約的里程碑付款
• 消化系統專利費率

第4章：消化系統領域的主要交易和相關人員

• 介紹
• 在消化系統合作領域最活躍的公司
• 消化系統領域交易最活躍的公司名單
• 腸胃產品超值優惠（依價格排序）

第5章：消化系統合約文件清單

• 介紹
• 與消化系統相關的合作協議（如有）

第6章：基於治療標靶的胃腸道藥物交易

• 介紹
• 消化系統治療標靶交易
• 特價優惠列表
• 特價優惠清單 - 各公司提供的消化系統相關產品特價優惠 (AZ)
• 交易清單 -消化系統相關交易（依技術類型分類）
• 交易類型的定義
• 關於這家研究公司
• Current Partnering
• 目前合約
• 理想合作夥伴最新報告的標題

The definitive benchmark for gastrointestinal dealmaking

Gastrointestinal partnering spans a broad range of indications, modalities, and stages of development, with deal structures reflecting the diversity of disease areas and therapeutic approaches across the space.

This report provides a comprehensive and structured analysis of 432 gastrointestinal collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how gastrointestinal deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by stage, asset type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a diverse and evolving therapeutic landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within gastrointestinal partnerships, particularly across chronic and heterogeneous disease settings.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark live transactions
• Prepare for negotiations with well-defined market context
• Evaluate partnership opportunities and counterparties
• Support internal strategy with robust, defensible data
• What's included
• 432 gastrointestinal collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy, and technology)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for gastrointestinal dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how gastrointestinal partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in gastrointestinal dealmaking

• 2.1. Introduction
• 2.2. Gastrointestinal partnering over the years
• 2.3. Gastrointestinal partnering by deal type
• 2.4. Gastrointestinal partnering by industry sector
• 2.5. Gastrointestinal partnering by stage of development
• 2.6. Gastrointestinal partnering by technology type
• 2.7. Gastrointestinal partnering by therapeutic indication

Chapter 3 - Financial deal terms for gastrointestinal partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for gastrointestinal partnering
• 3.3. Gastrointestinal partnering headline values
• 3.4. Gastrointestinal deal upfront payments
• 3.5. Gastrointestinal deal milestone payments
• 3.6. Gastrointestinal royalty rates

Chapter 4 - Leading gastrointestinal deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in gastrointestinal partnering
• 4.3. List of most active dealmakers in gastrointestinal
• 4.4. Top gastrointestinal deals by value

Chapter 5 - Gastrointestinal contract document directory

• 5.1. Introduction
• 5.2. Gastrointestinal partnering deals where contract document available

Chapter 6 - Gastrointestinal dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by gastrointestinal therapeutic target
• Deal directory
• Deal directory - Gastrointestinal deals by company A-Z
• Deal directory - Gastrointestinal deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Gastrointestinal partnering since 2016
• Figure 2: Gastrointestinal partnering by deal type since 2016
• Figure 3: Gastrointestinal partnering by industry sector since 2016
• Figure 4: Gastrointestinal partnering by stage of development since 2016
• Figure 5: Gastrointestinal partnering by technology type since 2016
• Figure 6: Gastrointestinal partnering by indication since 2016
• Figure 7: Gastrointestinal deals with a headline value
• Figure 8: Gastrointestinal deals with upfront payment values
• Figure 9: Gastrointestinal deals with milestone payment
• Figure 10: Gastrointestinal deals with royalty rates
• Figure 11: Active gastrointestinal dealmaking activity since 2016
• Figure 12: Top gastrointestinal deals by value since 2016